Seaport Therapeutics, Inc.
About Seaport Therapeutics, Inc.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $871.8M
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $871.8M
- Shares outstanding
- 50.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 1, 2026
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 14% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Seaport Therapeutics, Inc..
